Top Abstract Purchase Related
Home
>
Node
>
Subnode

Promising therapeutic options in triple-negative breast cancer

Bilici, A.; Arslan, C.; Altundag, K.

Journal of BUON Official Journal of the Balkan Union of Oncology 17(2): 209-222

2012

ISSN/ISBN: 1107-0625
PMID: 22740196
Document Number: 662516
Triple-negative breast cancer (TNBC) has a greater risk of recurrence despite more aggressive therapy even in lowrisk category. TNBC is high grade, hormone receptor and HER-2 negative, it exhibits a high level of Ki-67 staining and expresses the epithelial growth factor receptor (EGFR). Because of its expression profile, treatment options are limited to cytotoxic chemotherapy. Molecular defects that give rise to BRCA1-associated breast cancer also occur in TNBC. Thus, the combination of poly-(ADP-ribose)-polymerase (PARP) inhibitors with drugs that cause DNA breakages, such as alkylating agents and topoisomerase I inhibitors, could theoretically potentiate the efficacy of each drug in patients with TNBC. Clinical trials with various targeted approaches alone or in combination with different chemotherapeutic agents are currently underway. In this review, current and future treatment approaches in TNBC with novel targeted agents are discussed.

Document emailed within 1 workday
Secure & encrypted payments

Collignon, J.; Struman, I.; Tabruyn, S.; Josse, C.; Boukerroucha, M.; Jerusalem, G.; Bours, V. 2011: Molecular and genetic aspects of triple negative breast cancer and therapeutic implications Revue Medicale de Liege 66(5-6): 393-396
Giuliani, S.; Leonardi, E.; Aldovini, D.; Bernardi, D.; Pellegrini, M.; Soli, F.; Ferro, A.; Dalla Palma, P.; Decarli, N.; Barbareschi, M. 2012: Frequency of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from Trentino, North East Italy Pathologica 104(3): 93-97
Vincent-Salomon, A. 2013: Triple-negative breast cancer La Revue du Praticien 63(10): 1391-1392
Herold, C.I.; Anders, C.K. 2013: New targets for triple-negative breast cancer Oncology 27(9): 846-854
Zhang, M.; Zhou, Y.; Hu, Y.; Zhang, J. 2015: Effects of NVP-BKM120 on the triple-negative breast cancer cell Zhonghua Yi Xue Za Zhi 95(40): 3308-3312
Mel'nikov, D.I.; Pushina, I.V.; Lagereva, I.G.; Beĭkin, I.B.; Ivanova, I.I. 2013: Immunologic differences of triple-negative and luminal a breast cancer Voprosy Onkologii 59(3): 390-392
Hadadi, A.; Dale, P.; Fancher, C.; Lian, B. 2018: The Treatment of Triple Negative Breast Cancer: Does Insurance Status Matter? American Surgeon 84(7): 259-261
Toh, U.; Saku, S.; Okabe, M.; Iwakuma, N.; Kimitsuki, Y.; Akashi, M.; Ogo, E.; Yamada, A.; Shichijo, S.; Itoh, K.; Akagi, Y. 2016: Development of Peptide Vaccines for Triple-Negative Breast Cancer Treatment Gan to Kagaku Ryoho. Cancer and ChemoTherapy 43(10): 1249-1251
Garber, J. 2017: Judy Garber on PARP Inhibitors for Triple-Negative Breast Cancer Oncology 31(11): 814
Mise, M.; Higashide, S.; Hashimoto, K.; Kawada, K.; Hanaki, K.; Kanda, Y.; Niikawa, Y.; Miyamoto, N.; Takeuchi, A.; Sawada, S.; Mikami, Y.; Noda, H. 2009: Clinicopathological features of young patients with triple negative breast cancer Gan to Kagaku Ryoho. Cancer and ChemoTherapy 36(10): 1677-1681
2011: Categorization of triple-negative breast cancer patients will help in targeted therapy selection Oncology 25(9): 849
Sikov, W.M. 2017: Which patients with early-stage triple-negative breast cancer should receive a platinum? Clinical Advances in Hematology and Oncology: H&o 15(7): 510-514
Miao, P-tian.; Tong, Z-sheng.; Hao, C-fang.; Zhang, L. 2010: Prognostic analysis of patients with metastatic triple-negative breast cancer: a report of 120 cases Zhonghua Yi Xue Za Zhi 90(40): 2848-2851
Song, N.; Liang, B.; Wang, D. 2016: The function of MiR-21 expression differences and pathogenesis on familial and triple negative breast Cancer serum Pakistan Journal of Pharmaceutical Sciences 29(2 Suppl): 679-684
Gerson, R.; Alban, F.; Villalobos, A.; Serrano, A. 2008: Recurrence and survival rates among early breast cancer cases with triple negative immunophenotype Gaceta Medica de Mexico 144(1): 27-34
Budakoglu, B.; Altundag, K.; Aksoy, S.; Kaplan, M.A.; Ozdemir, N.Y.; Berk, V.; Ozkan, M.; Algin, E.; Kandemir, N.; Dogu, G.G.; Harputluoglu, H.; Arslan, U.Y.; Coskun, U.; Isikdogan, A.; Oksuzoglu, B. 2014: Outcome of 561 non-metastatic triple negative breast cancer patients: multi-center experience from Turkey Journal of BUON: Official Journal of the Balkan Union of Oncology 19(4): 872-878
Fayaz, S.; Demian, G.A.; El-Sherify, M.; Eissa, H.; Aziz, M.; Abuzallouf, S. 2019: Triple Negative Breast Cancer: 10-Year Survival Update of The Applied Treatment Strategy in Kuwait Gulf Journal of Oncology 1(29): 53-59
Wang, N.; Wang, Y.-j. 2010: How to optimize the clinical therapeutic protocol for triple-positive breast cancer Zhonghua Zhong Liu Za Zhi 32(4): 241-243
Chekhun, V.F.; Zhylchuk, V.E.; Lukyanova, N.Y.; Vorontsova, A.L.; Kudryavets, Y.I. 2009: Expression of drug resistance proteins in triple-receptor-negative tumors as the basis of individualized therapy of the breast cancer patients Experimental Oncology 31(2): 123-124
Riaz, A.; Rasul, A.; Hussain, G.; Zubair, M.; Samiullah, K.; Sarfraz, I.; Masood, M.; Jabeen, F.; Sultana, T.; Sultana, S. 2019: Eriocalyxin B induces apoptosis in human triple negative breast cancer cells via inhibiting STAT3 activation and mitochondrial dysfunction Pakistan Journal of Pharmaceutical Sciences 32(6 Supplary): 2843-2848